Novavax Inc (NVAX)
$14.94
0.00 (0.00%)
NVAX Stock Quote Delayed 30 Minutes
4 Pharma Stocks to Buy Even if the Pandemic Ends
Here are four pharma stocks that looks attractive for the long-term. Deep product development pipelines will ensure steady revenue and cash flow growth.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.11B
PE Ratio
-4.67
EPS
-3.2
Volume (Avg. Vol.)
17,555
Day's Range
-
52-Week Range
$3.53 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Dump Novavax Stock as Delays May Make Its Vaccine Practically Obsolete
Novavax's share price is down 41% year-to-date, bringing its six month decline to 63%, as the prospects of the biopharmaceutical company bringing a vaccine against Covid-19 to market grow dimmer by the hour.
Novavax Stock Is at Risk Despite Positive Poll Results
A recent poll supports Novavax's Covid treatment in the United States, but the vote on today's NVAX stock price chart warns against buying.
Novavax Just Can’t Get it Together
Patient investors should wait for NVAX stock to hit another low or for the FDA to approve its Covid-19 vaccine before investing.
Novavax Stock Has Growth Ahead Whether It Missed the Boat or Not
NVAX stock has been derided as a ran in the vaccine race, avoid that narrative and remain optimistic because the best is ahead for Novavax.
Why I’m Done With Novavax Stock
Management is terrible at delivering on its promises and even good news has failed to translate into higher prices for NVAX stock.
Shipment Delays Threaten the Best Advantage Novavax Has
The latest setback for NVAX stock is lower than expected delivery numbers for its Covid-19 vaccine. The longer it takes to get its vaccine into arms, the more it risks losing a critical advantage.
Take a Leap Into Novavax Stock After Vaccine Sales Start
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.
NVAX Stock Alert: Why Is Novavax Plunging Today?
Novavax hasn't delivered on an important 2021 promise. The future of NVAX stock looks grim as the vaccine race winds to a tentative close.
NVAX Stock Alert: The Covid-19 Vaccine News Sending Novavax Higher Today
News that Australia has received its first shipment of Novavax's Covid-19 vaccine has NVAX stock taking off nearly 9% in today's trading.
2022 Could be a Success or a Lost Opportunity for Novavax
Novavax, Inc. (NASDAQ:NVAX) has had a tough year with losses of approximately 68%. It has already declined about 37% year-to-date, as well. However, as of…
Novavax Can Still Succeed, But It’s Facing High Risks
Novavax's vaccine revenues haven't soared yet. But if the FDA approves the shot, the odds could change for NVAX stock.
Avoid Novavax for Now, Until the Picture Clears Up
NVAX stock may have seen a near-term bounce following the completion of filing of EUA filing with the FDA, but it may not be a buy yet.
Novavax Should Move Higher After International Distribution Efforts
In the wake of a multitude of positive press releases, NVAX stock traders should prepare for an imminent bounce in the share price.
NVAX Stock Alert: The HUGE Reason Novavax Is Shooting Higher Today
Today, investors in Novavax and NVAX stock got the news they were hoping for: the company announced an application with the FDA.
Novavax: The Fall of a Covid-19 Vaccine Star
Novavax has lagged in the vaccine delivery race, but is finally ready to delivery.
Novavax Could Be the Biggest Bargain in the Market Right Now
If Novavax gets finally its Emergency Use Authorization next month from the FDA, then you can expect NVAX stock to skyrocket.
Uncertain Market Conditions And Good News Make Novavax A Cautious Buy
An emergency use authorization in Australia is the latest example of the “yeah but” narrative that has plagued NVAX stock for the past year.
Novavax Continues to Require Patience, But It Should Pay Off
NVAX stock dropped precipitously of late, but investors with patience and a long view won't lose that patience as revenues start to roll in.
